compound 3i (666-15)

Catalog No.S8846

For research use only.

Compound 3i (666-15) is a potent and selective inhibitor of CREB-mediated gene transcription (IC50 = 0.081 ± 0.04 μM) and also potently inhibits cancer cell growth without harming normal cells.

compound 3i (666-15) Chemical Structure

CAS No. 1433286-70-4

Selleck's compound 3i (666-15) has been cited by 4 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description Compound 3i (666-15) is a potent and selective inhibitor of CREB-mediated gene transcription (IC50 = 0.081 ± 0.04 μM) and also potently inhibits cancer cell growth without harming normal cells.
Targets
CREB [1]
()
81 nM
In vitro

666-15 could potently inhibit cancer cell growth. In MDA-MB-231 and MDA-MB-468 cells, the GI50 for 666-15 is 73 and 46 nM, respectively. In A549 and MCF-7 cells, it exhibit robust activity as well with GI50 of 0.47 and 0.31 μM. 666-15 inhibits CREB’s transcription activity in living cells independent of direct CREB or CBP binding interaction[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-468 MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M4DOWVczKGi{cx?= MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIHfyc5d1cCCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODR4zszN NE[xcmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g3Pyd-Mk[wNlM5Pjd:L3G+
MDA-MB-231 M1S3NGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVSzcXI{PzJiaILz NX;LSlh3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OD1yLkC3N:69VQ>? NYT5dVc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5PjdpPkK2NFI{QDZ5PD;hQi=>
HEK293T NVrsb4xuTnWwY4Tpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKEOURVKtcYVlcWG2ZXSg[4Vv\SC2cnHud4NzcXC2aX;uJIlvKGi3bXHuJGhGUzJ7M2SgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyQ2LFMXJNfWNiYomgdoVvcWyuYTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR|UxRTBwMEix{txO NVrSXJZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5PjdpPkK2NFI{QDZ5PD;hQi=>
HEK293T MYXGeY5kfGmxbjDhd5NigQ>? MYGzNEBucW6| MY\Jcohq[mm2aX;uJI9nKEOURVKgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIH\vdpNsd2yrbj3pcoR2[2WmIFPSSWIhfHKjboPjdolxfGmxbjDhZ5Rqfmm2eTDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuNFgy|ryP MmjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF5NkWxOFMoRjNzN{[1NVQ{RC:jPh?=
MCF7 NYX0OYc2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NYW1VXg6PzJiaILz MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxRTBwM{JOwG0> MkfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4OlcoRjJ4MEKzPFY4RC:jPh?=
A549 NE\QUWRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnT6O|IhcHK| NXPvd5FlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2wMlQ4|ryP NGjLR|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g3Pyd-Mk[wNlM5Pjd:L3G+
HEK293T NHO4OoRHfW6ldHnvckBie3OjeR?= NYHzenhEOzBibXnudy=> MUXJcohq[mm2aX;uJI9nKE6Ia3HwdIFDKCi3bnvuc5dvKG:{aXfpckkudWWmaXH0[YQh\2WwZTD0doFve2O{aYD0bY9vKGmwIHj1cYFvKEiHS{K5N3Qh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDhckBPTmujcIDhRkBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSg[4Vv\SC2cnHud4NzcXC2aX;uJJBz\XS{ZXH0[YQh\m:{IEOwJI1qdnNibXXhd5Vz\WRiYX\0[ZItKEmFNUC9OU4zQc7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{i2O{c,OjZyMkO4Olc9N2F-
HEK293T MlnwSpVv[3Srb36gZZN{[Xl? Mn61OVAhdk1? MmqzNUBpeg>? M4\wXWlvcGmkaYTpc44hd2ZiQ2LFRk1u\WSrYYTl[EBo\W6nIITyZY5{[3KrcITpc44hcW5iaIXtZY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIH\vdpNsd2yrbj3zeIlufWyjdHXkJG52enJzL17SOGEzKHS{YX7zZ5JqeHSrb36gZZQhPTBibl2gZYZ1\XJiMTDodkBjgSCzUmStVGNVKGGwYXz5d4l{ NEH2VHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g3Pyd-Mk[wNlM5Pjd:L3G+
HEK293T MnnZSpVv[3Srb36gZZN{[Xl? MXm+JFEhfU1? NFj5T4Q{OCCvaX7z MV;Jcohq[mm2aX;uJI9nKF[SMU[vR3JGSiBqdX7rco94diCxcnnnbY4qKGmwdHXyZYN1cW:wIHnuJIh2dWGwIFjFT|I6O1RiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBnd3K|a3;sbY4ue3SrbYXsZZRm\CCpZX7lJJRz[W6|Y4LpdJRqd25iYYSgQkAyKHWPIHHmeIVzKDNyIH3pcpMh[nliQ2LFMXJNfWNiY3;tdIxmdWWwdHH0bY9vKGG|c3H5 MnLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4OlcoRjJ4MEKzPFY4RC:jPh?=
HEK293T MmjFSpVv[3Srb36gZZN{[Xl? MoHpQkAyKHWP NUPJT5NvOzBibXnudy=> MVjJcohq[mm2aX;uJI9nKFB3MzCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKGi3bXHuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCob4Lzb49tcW5vc4TpcZVt[XSnZDDn[Y5mKHS{YX7zZ5JqeHSrb36gZZQhRiBzIIXNJIFnfGW{IEOwJI1qdnNiYomgR3JGNVKOdXOgZ49ueGynbXXueIF1cW:wIHHzd4F6 NVnlbVY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5PjdpPkK2NFI{QDZ5PD;hQi=>
MDA-MB-468 MVrBcpRqfHWvb4KgZZN{[Xl? NU\uOnlQOTBibXevb4c> NFvz[ok2KHenZXvz MofhRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR4ODDj[YxteyC6ZX7v[5Ji\nSnZDDpckBDSUyEL3OgcY92e2ViYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHS3bX;yJJZwdHWvZTDheEAyOCCvZz;r[{whcXBib37j[UBiKGSjeTygOUBl[Xm|IIDldkB4\WWtIH\vdkA2KHenZXvzJJJmdGG2aY\lJJRwKGOxboTyc4w> NYTrUFBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5PjdpPkK2NFI{QDZ5PD;hQi=>
HEK293T MWHGeY5kfGmxbjDhd5NigQ>? MnXyNVAxKG6P MmHRNUBpeg>? MX;Jcohq[mm2aX;uJI9nKEOURVKgbY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIF\zb{1qdmS3Y3XkJG5TPEF{IHflcoUh\XiycnXzd4lwdiCjdDCxNFAhdk1icILlMYlv[3WkYYTl[EBnd3JiMTDodkBj\W[xcnWgSpNsKHO2aX31cIF1cW:wIH\vdkA1PSCvaX7zJIJ6KHGUVD3QR3Ih[W6jbInzbZM> MkK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF5NkWxOFMoRjNzN{[1NVQ{RC:jPh?=
In vivo

In an in vivo MDA-MB-468 xenograft model, 666-15 completely suppresses the tumor growth without overt toxicity. Preliminary toxicity studies show that intraperitoneal (ip) injection of 10 mg/kg of 666-15 is well tolerated in mice[1].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: HEK 293T cells
  • Concentrations: 0.05, 0.1, 0.5 μM
  • Incubation Time: --
  • Method:

    HEK 293T cells are treated with different concentrations of 666-15 followed by treatment with forskolin. Then the relative mRNA level of Nurr1/NR4A2 is determined by qRT-PCR analysis.

Animal Research:

[1]

  • Animal Models: 6- to 8-week old BALB/c nude mouse inoculated subcutaneously at the right flank with MDA-MB-468 cells
  • Dosages: 10 mg/kg
  • Administration: IP

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(161.15 mM)
Ethanol 3 mg/mL
(4.83 mM)
Water Insoluble

Chemical Information

Molecular Weight 620.52
Formula

C33H31Cl2N3O5

CAS No. 1433286-70-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C=C(C(=CC2=C1)C(=O)NCCOC3=CC4=CC=CC=C4C=C3C(=O)NC5=C(C=C(C=C5)Cl)O)OCCCN.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy compound 3i (666-15) | compound 3i (666-15) supplier | purchase compound 3i (666-15) | compound 3i (666-15) cost | compound 3i (666-15) manufacturer | order compound 3i (666-15) | compound 3i (666-15) distributor